News

Results showed high levels of response in patients with relapsed or refractory classical Hodgkin Lymphoma (HL), with an overall response rate of 87% (n=20) and stable disease in

AML is an aggressive and deadly type of blood cancer, in which the body produces too many of a specific type of white blood cell (myeloblast), which can

The data from the AETHERA trial were featured at the 56th American Society of Hematology (ASH) Annual Meeting press program today and will be presented in an oral

During the trial, 30 patients with stage III-IV melanoma received about four cycles of pIL-12 EP into superficial cutaneous, subcutaneous and nodal lesions on days one, five and

The trial is designed to evaluate CPI-613, in combination with bendamustine and rituximab, in these NHL patients. CPI-613 is a first-in-class anticancer compound designed to disrupt the altered

Sources close to the matter have been cited by The Wall Street Journal as saying that the deal could be announced as early as this week. The acquisition

The application covers composition of matter for KP415, the company’s NME prodrug of methylphenidate. KP415 is designed to be a controlled release (CR), abuse-deterrent methylphenidate product and is

According to the European Centre for Disease Prevention and Control (ECDC), every year about 25,000 people die from antibiotic-resistant healthcare-associated infections in the EU. Basilea chief commercial officer

Astellas will regain all rights granted to Janssen after termination and the company is considering future plan for ASP015K outside Japan. The company will continue the phase III